GH safety workshop position paper: A critical appraisal of recombinant human GH therapy in children and adults

D. B. Allen; P. Backeljauw; M. Bidlingmaier; B. M.K. Biller; M. Boguszewski; P. Burman; G. Butler; K. Chihara; J. Christiansen; S. Cianfarani; P. Clayton; D. Clemmons; P. Cohen; F. Darendeliler; C. Deal; D. Dunger; E. M. Erfurth; J. S. Fuqua; A. Grimberg; M. Haymond; C. Higham; K. Ho; A. R. Hoffman; A. Hokken-Koelega; G. Johannsson; A. Juul; J. Kopchick; P. Lee; M. Pollak; S. Radovick; L. Robison; R. Rosenfeld; R. J. Ross; L. Savendahl; P. Saenger; H. Toft Sorensen; K. Stochholm; C. Strasburger; A. Swerdlow; M. Thorner

doi:10.1530/EJE-15-0873

GH safety workshop position paper: A critical appraisal of recombinant human GH therapy in children and adults

D. B. Allen, P. Backeljauw, M. Bidlingmaier, B. M.K. Biller, M. Boguszewski, P. Burman, G. Butler, K. Chihara, J. Christiansen, S. Cianfarani, P. Clayton, D. Clemmons, P. Cohen, F. Darendeliler, C. Deal, D. Dunger, E. M. Erfurth, J. S. Fuqua, A. Grimberg, M. HaymondC. Higham, K. Ho, A. R. Hoffman, A. Hokken-Koelega, G. Johannsson, A. Juul, J. Kopchick, P. Lee, M. Pollak, S. Radovick, L. Robison, R. Rosenfeld, R. J. Ross, L. Savendahl, P. Saenger, H. Toft Sorensen, K. Stochholm, C. Strasburger, A. Swerdlow, M. Thorner

Pediatrics

Research output: Contribution to journal › Article › peer-review

176 Scopus citations

Abstract

Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-Term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-Term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

Original language	English (US)
Pages (from-to)	P1-P9
Journal	European journal of endocrinology
Volume	174
Issue number	2
DOIs	https://doi.org/10.1530/EJE-15-0873
State	Published - Feb 2016

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1530/EJE-15-0873

Cite this

Allen, D. B., Backeljauw, P., Bidlingmaier, M., Biller, B. M. K., Boguszewski, M., Burman, P., Butler, G., Chihara, K., Christiansen, J., Cianfarani, S., Clayton, P., Clemmons, D., Cohen, P., Darendeliler, F., Deal, C., Dunger, D., Erfurth, E. M., Fuqua, J. S., Grimberg, A., ... Thorner, M. (2016). GH safety workshop position paper: A critical appraisal of recombinant human GH therapy in children and adults. European journal of endocrinology, 174(2), P1-P9. https://doi.org/10.1530/EJE-15-0873

Allen, DB, Backeljauw, P, Bidlingmaier, M, Biller, BMK, Boguszewski, M, Burman, P, Butler, G, Chihara, K, Christiansen, J, Cianfarani, S, Clayton, P, Clemmons, D, Cohen, P, Darendeliler, F, Deal, C, Dunger, D, Erfurth, EM, Fuqua, JS, Grimberg, A, Haymond, M, Higham, C, Ho, K, Hoffman, AR, Hokken-Koelega, A, Johannsson, G, Juul, A, Kopchick, J, Lee, P, Pollak, M, Radovick, S, Robison, L, Rosenfeld, R, Ross, RJ, Savendahl, L, Saenger, P, Toft Sorensen, H, Stochholm, K, Strasburger, C, Swerdlow, A & Thorner, M 2016, 'GH safety workshop position paper: A critical appraisal of recombinant human GH therapy in children and adults', European journal of endocrinology, vol. 174, no. 2, pp. P1-P9. https://doi.org/10.1530/EJE-15-0873

@article{b8b017f75e3044f2a5a582b7797a13a0,

title = "GH safety workshop position paper: A critical appraisal of recombinant human GH therapy in children and adults",

abstract = "Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-Term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-Term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.",

author = "Allen, {D. B.} and P. Backeljauw and M. Bidlingmaier and Biller, {B. M.K.} and M. Boguszewski and P. Burman and G. Butler and K. Chihara and J. Christiansen and S. Cianfarani and P. Clayton and D. Clemmons and P. Cohen and F. Darendeliler and C. Deal and D. Dunger and Erfurth, {E. M.} and Fuqua, {J. S.} and A. Grimberg and M. Haymond and C. Higham and K. Ho and Hoffman, {A. R.} and A. Hokken-Koelega and G. Johannsson and A. Juul and J. Kopchick and P. Lee and M. Pollak and S. Radovick and L. Robison and R. Rosenfeld and Ross, {R. J.} and L. Savendahl and P. Saenger and {Toft Sorensen}, H. and K. Stochholm and C. Strasburger and A. Swerdlow and M. Thorner",

note = "Publisher Copyright: {\textcopyright} 2016 The authors Published by Bioscientifica Ltd.",

year = "2016",

month = feb,

doi = "10.1530/EJE-15-0873",

language = "English (US)",

volume = "174",

pages = "P1--P9",

journal = "European journal of endocrinology",

issn = "0804-4643",

publisher = "BioScientifica Ltd.",

number = "2",

}

TY - JOUR

T1 - GH safety workshop position paper

T2 - A critical appraisal of recombinant human GH therapy in children and adults

AU - Allen, D. B.

AU - Backeljauw, P.

AU - Bidlingmaier, M.

AU - Biller, B. M.K.

AU - Boguszewski, M.

AU - Burman, P.

AU - Butler, G.

AU - Chihara, K.

AU - Christiansen, J.

AU - Cianfarani, S.

AU - Clayton, P.

AU - Clemmons, D.

AU - Cohen, P.

AU - Darendeliler, F.

AU - Deal, C.

AU - Dunger, D.

AU - Erfurth, E. M.

AU - Fuqua, J. S.

AU - Grimberg, A.

AU - Haymond, M.

AU - Higham, C.

AU - Ho, K.

AU - Hoffman, A. R.

AU - Hokken-Koelega, A.

AU - Johannsson, G.

AU - Juul, A.

AU - Kopchick, J.

AU - Lee, P.

AU - Pollak, M.

AU - Radovick, S.

AU - Robison, L.

AU - Rosenfeld, R.

AU - Ross, R. J.

AU - Savendahl, L.

AU - Saenger, P.

AU - Toft Sorensen, H.

AU - Stochholm, K.

AU - Strasburger, C.

AU - Swerdlow, A.

AU - Thorner, M.

PY - 2016/2

Y1 - 2016/2

N2 - Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-Term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-Term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

AB - Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-Term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-Term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

UR - http://www.scopus.com/inward/record.url?scp=84956654819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956654819&partnerID=8YFLogxK

U2 - 10.1530/EJE-15-0873

DO - 10.1530/EJE-15-0873

M3 - Article

C2 - 26563978

AN - SCOPUS:84956654819

SN - 0804-4643

VL - 174

SP - P1-P9

JO - European journal of endocrinology

JF - European journal of endocrinology

IS - 2

ER -

GH safety workshop position paper: A critical appraisal of recombinant human GH therapy in children and adults

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this